Eigenvalue | Percentage Variance Explained | Sex | Group | No. OMERACT Meetings Attended (mean, SD) | Summary | |
---|---|---|---|---|---|---|
Factor One, n = 31 | 16.77 | 16 | 67.7% m, 32.3% f | 14 (45.2%) Researchers | 4.58 (3.09) | Evidence not eminence: These participants value the process of data and evidence being used to drive the research agenda at OMERACT. They believe that in reaching consensus the data are more important than eminence or personality. These delegates attend OMERACT to work rather than socialize |
8 (25.8%) Clinicians | ||||||
6 (19.4%) Industry | ||||||
2 (6.5%) Patients | ||||||
1 (3.1%) Fellows | ||||||
Factor Two, n = 19 | 12.98 | 12 | 52.6% m, 47.4% f | 15 (78.9%) Researchers | 5.11 (2.85) | Collaboration and collegiality: These participants value the interaction with other delegates. They believe that collaboration and discussion is an important part of the consensus process. They also value the opportunity to work together with like-minded people on the same intellectual level |
4 (21.1%) Clinicians | ||||||
Factor Three, n = 12 | 9.99 | 10 | 66.7% m, 333% f | 7 (58.3%) Researchers | 4.17 (2.48) | Equal voices, equal votes, common goals: These participants believe in equality and striving toward a common goal. They value the OMERACT process that gives all delegates an equal voice in the discussions with everyone being encouraged to contribute and that the equal voting process is important. These participants value the common goals of guiding the conduct of clinical trials and reaching consensus above personal recognition and gain |
3 (25.0%) Clinicians | ||||||
2 (16.7%) Industry | ||||||
Factor Four, n = 8 | 6.56 | 6 | 62.5% m, 37.5% f | 7 (87.5%) Researchers | 4.50 (2.45) | Principles and product, not process: These participants value the overall principles of OMERACT: namely the focus on outcome measures. They also value the product of OMERACT such as guiding the conduct of clinical trials. However, these participants were unconvinced in the OMERACT process of transparency and equal voting, believing that this is not necessary or effective to achieve the end product |
1 (12.5%) Clinicians | ||||||
Confounded | n/a | n/a | 54.5% m, 45.5% f | 9 (40.9%) Researchers | 4.00 (2.12) | n/a |
5 (22.7%) Clinicians | ||||||
1 (4.6%) Industry | ||||||
5 (22.7%) Patients | ||||||
2 (9.1%) Fellows | ||||||
Non-significant | n/a | n/a | 53.8% m, 46.2% f | 7 (53.8%) Researchers | 3.54 (1.39) | n/a |
4 (30.8%) Clinicians | ||||||
2 (15.4%) Fellows | ||||||
Study population | n/a | 44 | 60% m, 40% f | 59 (56.2%) Researchers | 4.36 (2.54) | n/a |
25 (23.8%) Clinicians | ||||||
9 (8.6%) Industry | ||||||
7 (6.7%) Patients | ||||||
5 (4.8%) Fellows |
n/a: not applicable.